Kyntra Bio, Inc.
Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -3.76 | $4M | -$14M |
| 2025 Q4 | -2.41 | $1M | -$18M |
| 2025 Q3 | 49.61 | $1M | -$2M |
| 2025 Q2 | -1.88 | $1M | $13M |
| 2025 Q1 | 0.05 | $3M | $3M |
| 2024 Q4 | 4.50 | -$123M | -$31M |
| 2024 Q3 |
| -4.25 |
| $46M |
| -$8M |
| 2024 Q2 | -3.89 | $998,000 | -$40M |